Últimas noticias sobre Loar Holdings (NYSE:LOAR) Bolsa

Loar Holdings

Loar Holdings Inc in the design, manufacture, and sale of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Its manufactured products includes auto throttles, lap-belt airbags, two- and three-point seat belts, water purification systems, fire barriers, polyimide washers and bushings, latches, hold-open and tie rods, temperature and fluid sensors and switches, carbon and metallic brake discs, fluid and pneumatic-based ice protection, RAM air components, sealing solutions and motion and actuation devices, among others. It operate across ten manufacturing facilities located in the United States, one manufacturing facility in Germany and one manufacturing facility in the United Kingdom (UK).

Loar Holdings Inc

Ulta Beauty Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) shares are trading higher in Monday&#8217;s after-hours session after the company announced a CEO transition and <a href="https://www.benzinga.com/pressreleases/25/01/b42830392/ulta-beauty-announces-ceo-transition">updated its near-term outlook</a>.
What Happened: After the market close on Monday, Ulta announced that Dave Kimbell will retire as CEO and step down from the company&#8217;s board, effective immediately.
President and COO Kecia Steelman will succeed Kimbell as president and CEO, effective as of Monday. Steelman will also join the company&#8217;s board. 
&#8220;Kecia is a world-class business executive with deep beauty and retail expertise, an unwavering commitment to effective execution, and a profound passion for our guests and associates. She has been instrumental in developing our recently refreshed strategic framework, and we are confident that she is the right person to lead Ulta Beauty forward,&#8221; said Lorna Nagler, chair of Ulta Beauty&#8217;s board.
See Also: <a href="https://www.benzinga.com/25/01/42825782/bath-body-works-loyalty-program-shines-in-holiday-sales-says-analyst">Bath &amp; Body Works Undervalued: Goldman Sachs Sees Upside Amid Strong Candle Day Performance</a>
In addition to the CEO transition, Ulta updated its fourth-quarter guidance to reflect stronger-than-expected performance during the holiday season. 
The company now expects comparable sales to &#8220;increase modestly.&#8221; Ulta also said it expects operating margin to be above the high-end of the company&#8217;s previous expected range of&nbsp;11.6%&nbsp;to&nbsp;12.4% of sales. 
Ulta is scheduled to report fourth-quarter financial results on March 13. Analysts currently expect the company to report earnings of $6.73 per share and revenue of $3.4 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;I am confident the strategic priorities we shared last fall will enable us to capture greater market share in beauty and wellness and deliver long-term profitable growth, and I am excited to lead our outstanding teams as we unlock even greater advantages of our operating model, drive best-in-class execution, and position Ulta Beauty for our next chapter of growth as the beauty destination for a lifetime,&#8221; Steelman said. 
ULTA Price Action: <a href="http://benzinga.com/quote/ulta">Ulta Beauty shares</a> were up 2.48% after hours, trading at $442 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

News

Guidance

Management

After-Hours Center

Movers

General

ULTA

Ulta Beauty Stock Is Rising After Hours: Here's Why

Graphic Packaging Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>) has outperformed the market over the past 15 years by 2.69% on an annualized basis producing an average annual return of 14.37%. Currently, Graphic Packaging Holding has a market capitalization of $7.94 billion. 
Buying $1000 In GPK: If an investor had bought $1000 of GPK stock 15 years ago, it would be worth $7,385.47 today based on a price of $26.44 for GPK at the time of writing.
<h3>Graphic Packaging Holding's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736199908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.stoketherapeutics.com%2F&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=Stoke+Therapeutics%2C+Inc.&amp;index=1&amp;md5=454f1331ad469e0bb2ff820d8c29374c">Stoke Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that its management team will host a webcast and conference call for investors and analysts to discuss successful alignment with global regulatory agencies related to a Phase 3 study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.
The webcast will be conducted Tuesday, January 7, 2025 at 8:00am Eastern Time and can be accessed from the Investors &amp; News section of Stoke's website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.stoketherapeutics.com%2F&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestor.stoketherapeutics.com%2F&amp;index=2&amp;md5=0cb1b30b6a3643c6103e41277dc36c53">https://investor.stoketherapeutics.com/</a>. Research analysts who plan to join the call and participate in the Q&amp;A session may register <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fregister.vevent.com%2Fregister%2FBIfb7a43c079834c3cb6a0813f54c1059e&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=here&amp;index=3&amp;md5=7af8fd1c74d79d04b91cc2894bac615b">here</a> to receive the dial-in details and a unique PIN. For all others, the listen-only webcast can be accessed by clicking <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2Fmj8c7ajk&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=here&amp;index=4&amp;md5=8eeec19293664ff83d3ffc6172d6dc34">here</a>. A replay of the webcast will be archived and available for at least 90 days following the event.

Biotech

Events

STOK

Stoke Therapeutics To Host Webcast To Discuss Successful Global Regulatory Alignment For A Phase 3 Study Of Zorevunersen As Potentially The First Disease Modifying Medicine For Dravet Syndrome On January 7, 2025 At 8:00am Eastern Time

Equus Appoints Fraser Atkinson As Chairman

– Mollie Leoni, M.D. promoted to Chief Medical Officer –
– Francis Burrows, Ph.D. promoted to Chief Scientific Officer –
– Stephen Dale, M.D., steps down as CMO and Head of R&amp;D to prioritize personal health –
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Mollie Leoni, M.D., has been promoted to Chief Medical Officer after serving as Executive Vice President of Clinical Development and clinical lead for the Company's ziftomenib program since 2020. In addition, Francis Burrows, Ph.D., has been promoted to Chief Scientific Officer after leading the Company's translational research efforts for the past nine years. Stephen Dale, M.D., has stepped down as Chief Medical Officer, effective as of January 2, 2025, to focus on recovery from personal health challenges.

KURA

Kura Oncology Announces Senior Executive Promotions; Mollie Leoni, Promoted To Chief Medical Officer; Stephen Dale Steps Down As CMO And Head Of R&D To Prioritize Personal Health

ENVX

Enovix Completes Site Acceptance Testing Of Fab2

Sheridan C. Swords, previously executive vice president, commercial liquids and natural gas gathering and processing, is assuming the newly created position of executive vice president and chief commercial officer.&nbsp;
 &nbsp;

ONEOK Names Randy N. Lentz To Newly Created Position Of Executive Vice President And COO;

<ul>
<li>Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivo</li>
<li>Programs to focus on silencing hard-to-drug targets of high therapeutic value in T cell-driven autoimmune diseases</li>
<li>Company reorganization supports evolution of ctLNP-enabled strategy and buildout of clinical capabilities ahead of first IND expected in 2H 2026</li>
</ul>
CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=027Hc0iV9b3bn31fIYu-D_K2UCwWK-kHIEeCWObZ_SYoKcLmk_FTbqmyuakhho9D_puGTMCU4fcrMVn_xRE377LIYsBdVqYhVAkwMl-lP1bnLAothOYz1lzNzcCUGCtUZ-ql2y8lzaklBO-Z3eX5LvyqZqdKorEbxHNadzB1MVHlTX8vWFpNiycqI5P_fTVwJyGqJwJziyyNlnFNSvbQ7DNZjz3EI11B6LKd-_LuIsOuQVtCVBoqV7eVloXCn-mLYI1FrHvSpQslCrcpjngxjg==">Generation Bio Co.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) a biotechnology company working to change what is possible for people living with T cell-driven autoimmune diseases, announced it is leveraging its validated T cell-directed lipid nanoparticle (ctLNP) to develop siRNA therapeutics to silence disease-driving targets in T cells.

GBIO

Generation Bio To Apply ctLNP Delivery Technology To Develop siRNA Therapeutics For T Cell-Driven Autoimmune Diseases

During the interim period until the transaction closes, Ansys will continue to offer Ansys PowerArtist as part of its product line, and is committed to providing the same high-quality service its customers have come to expect.

Asset Sales

ANSS

Ansys Says Sale Of PowerArtist Is Not Material To Its Financials; Terms Of Agreement Were Not Disclosed

Ansys and Synopsys determined that the sale of PowerArtist was necessary to obtain regulatory approval for Synopsys' proposed acquisition of Ansys.

KEYS

SNPS

Ansys Enters Definitive Agreement For Sale Of Its PowerArtist Business To Keysight Technologies

<ul>
<li>Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeks</li>
<li>Overall, DNL343 was found to be safe and well tolerated</li>
<li>Additional analyses, including neurofilament light (NfL) and other fluid biomarkers, prespecified sub-group analyses and analyses from the active treatment extension period are expected later in 2025 &nbsp;</li>
</ul>

DNLI

Denali Therapeutics Announces Topline Results For Regimen G Evaluating eIF2B Agonist DNL343 In Phase 2/3 HEALEY ALS Platform Trial; Study Did Not Meet Primary Endpoint

NNN REIT, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>), a real estate investment trust, today announced that Kevin B. Habicht, Executive Vice President, Chief Financial Officer, Assistant Secretary, Treasurer and the Company's principal financial officer, will retire and step down as a member of the Board of Directors effective March 31, 2025.&nbsp; Vincent H. Chao will join NNN as Executive Vice President on January 9, 2025, and assume the positions of Chief Financial Officer, Assistant Secretary and Treasurer and serve as the Company's principal financial officer effective April 1, 2025.
Mr. Habicht has served as Executive Vice President and Chief Financial Officer of the Company since December 1993, and as Treasurer of the Company since January 1998 and as a director of the Company since June 2000. Mr. Habicht served as Secretary of the Company from January 1998 to May 2003.

NNN REIT Announces Kevin B. Habicht, Executive Vice President, CFO, Assistant Secretary, Treasurer And The Co's Principal Financial Officer, Will Retire, Effective March 31, 2025. Vincent H. Chao Will Join As Executive Vice President On January 9, 2025, And Assume The Positions Of CFO, Assistant Secretary And Treasurer And Serve As The Co's Principal Financial Officer Effective April 1, 2025

Jack A. Hockema, Executive Chair of the Board of Directors and Chair of the Executive Committee of the Board, notified the Board of his decision to retire as a director of the Company, effective January 1, 2025.&nbsp;
&nbsp;

KALU

Kaiser Aluminum Names Keith A. Harvey,  Company's President, CEO And A Director, As Chairman Of The Board

Contracts

MPTI

MtronPTI Receives Over $10M Production Contract For A US Defense Program

Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) has outperformed the market over the past 5 years by 12.62% on an annualized basis producing an average annual return of 25.44%. Currently, Krystal Biotech has a market capitalization of $4.45 billion. 
Buying $1000 In KRYS: If an investor had bought $1000 of KRYS stock 5 years ago, it would be worth $3,017.82 today based on a price of $155.81 for KRYS at the time of writing.
<h3>Krystal Biotech's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736199008_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KRYS

Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today

Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), American Airlines Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) and Southwest Airlines Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) shares traded higher on Monday. Here&#8217;s what <a href="https://www.benzinga.com/general/travel/25/01/42809678/delta-southwest-american-and-others-airlines-halt-over-1300-flights-on-monday-after-severe-winter-storm">you need to know</a>.
What To Know: <a href="https://www.benzinga.com/general/travel/24/12/42705878/airline-stocks-outperform-tech-in-2024-holiday-travel-expected-to-see-records-this-year">Airlines</a> and other travel-related stocks moved higher on Monday after Transportation Security Administration (TSA) traveler screening data showed record travel figures for the end of 2024.
Near the end of last week, TSA <a href="https://x.com/TSA/status/1875202022737412371">posted</a> on X that it screened almost 39 million individuals from Dec. 19 through Jan. 2, marking its &#8220;busiest end of year travel period ever.&#8221; For all of 2024, TSA said officers screened a record 904 million people at airport checkpoints across the nation.
The government agency <a href="https://www.tsa.gov/travel/passenger-volumes/2024">reported</a> that 2,172,907 travelers were screened on New Year&#8217;s Eve, 2,039,342 were screened on Christmas and 1,551,896 were screened on Thanksgiving.
The increase in TSA screenings indicates strong demand for air travel during the holiday season, which may boost ticket sales and revenue for airlines. Additionally, the high number of passengers highlights the resilience of the travel industry, suggesting continued post-pandemic growth.
Investors won&#8217;t have to wait long to get holiday travel data from the airlines. Notably, Delta is expected to release 2024 fourth-quarter and fiscal-year earnings at the end of the week. Analysts expect quarterly earnings per share of $1.76 and revenue of $14.19 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>. Several other airlines are scheduled to report earnings in the coming weeks. 
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42828238/gemini-resolves-cftc-lawsuit-with-5m-settlement-over-bitcoin-futures-misstatements">Gemini Resolves CFTC Lawsuit With $5M Settlement Over Bitcoin Futures Misstatements</a>
DAL, AAL, LUV Price Action: Delta shares shares closed Monday up 1.75% at $60.03, American shares closed the day up 3.24% at $17.52 and Southwest shares closed up 0.62% at $33.82, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image via Shutterstock

Travel

What's Going On With Delta, American And Southwest Airlines Shares Monday?

APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) today announced key updates to its executive leadership and corporate officers.
Clay Bretches, executive vice president, Operations, has announced plans to retire July 1, 2025. As part of its commitment to maintaining excellence in operations, the company has launched an internal and external search for a new leader to drive continued innovation and operational efficiency. Bretches will remain with the organization and help ensure a smooth transition to a new leader, anticipated in the first half of 2025.

APA Corporation Announces Clay Bretches, Executive Vice President, Operations, Has Announced Plans To Retire July 1, 2025

New financing arrangement reduces Company's cost of capital by approximately 40%
Further enhances financial flexibility, cash generation and ability to support growth strategy
CHICAGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- FreightCar America, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) ("FreightCar America" or the "Company"), a diversified manufacturer and supplier of railroad freight cars, railcar parts and components, today announced it has completed a new term loan facility. The proceeds from the term loan will be used to redeem all outstanding shares of Series C Preferred Stock, as well as settle all related accrued dividends.
Highlights:
<ul>
<li>The Company closed a $115 million 4-year term loan agreement on December 31st, 2024 (the "Term Loan").</li>
<li>Proceeds from the Term Loan were used to redeem all 85,412 shares of Series C Preferred Stock that were outstanding and all accrued dividends as of December 31st, 2024.</li>
<li>The Term Loan is priced at SOFR + 600, which will reduce the Company's existing cost of capital by approximately 40%, resulting in savings of approximately $9.2 million in the first year, or approximately $0.26 per share on a fully diluted basis.</li>
</ul>

Financing

RAIL

FreightCar America Announces Agreement To Redeem All Outstanding Preferred Shares With New Term Loan; New Financing Arrangement Reduces Company's Cost Of Capital By ~40%

CX-2051 (EpCAM PROBODY ADC) has been prioritized as the Company's lead program with an initial focus in advanced metastatic CRC.
Early-stage research and platform capabilities to be concentrated on existing and potential future partnerships during 2025.
&nbsp;

CTMX

CytomX Therapeutics Expects Revised Focus And Associated Cost And Headcount Reductions  To Extend Cash Runway Into Q2 Of 2026

Macquarie analyst Tim Nollen maintains Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) with a Neutral and maintains $42 price target.

Price Target

Analyst Ratings

CMCSA

Macquarie Maintains Neutral on Comcast, Maintains $42 Price Target

Loar launches equity offering

Loar prices upsized offering of 5.75M shares

The deal size was increased to 5.75M shares in common stock from 4.75M shares in common stock. Jefferies, Moelis, Morgan Stanley, Citi, Blackstone ...

Loar Holdings 5.75M share Secondary priced at $85.00

There's a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Loar Holdings Inc. (LOAR – Research Report) and Core Scienti...

Analysts Offer Insights on NA Companies: Loar Holdings Inc. (LOAR) and Core Scientific Inc (CORZ)

Morgan Stanley raised the firm's price target on Loar Holdings (LOAR) to $91 from $89 and keeps an Equal Weight rating on the shares. 2025 presents...

Loar Holdings price target raised to $91 from $89 at Morgan Stanley

Morgan Stanley analyst Kristine Liwag maintained a Hold rating on Loar Holdings Inc. (LOAR – Research Report) yesterday and set a price target of $...

Morgan Stanley Remains a Hold on Loar Holdings Inc. (LOAR)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Loar Holdings (NYSE:<a href="https://investorplace.com/stock-quotes/loar-stock-quote/">LOAR</a>) just reported results for the second quarter of 2024.<ul><li>Loar Holdings reported earnings per share of 9 cents. This was below the analyst estimate for EPS of 10 cents.</li><li>The company reported revenue of $97.02 million.</li><li>This was 5.80% better than the analyst estimate for revenue of $91.70 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	
	The post <a href="https://investorplace.com/earning-results/2024/08/loar-stock-earnings-loar-holdings-for-q2-of-2024/">LOAR Stock Earnings: Loar Holdings Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Comments

Loar Holdings

Noticias

Últimas noticias sobre Loar Holdings (NYSE:LOAR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL